Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	At The Market Offering	Common Stock Financings	Pre-Funded Warrants	Common Stock	Common Stock At The Market Offering	Common Stock Common Stock Financings	Common Stock Pre-Funded Warrants	Additional Paid-in Capital	Additional Paid-in Capital At The Market Offering	Additional Paid-in Capital Common Stock Financings	Additional Paid-in Capital Pre-Funded Warrants	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balance at Dec. 31, 2023	$ 287,506				$ 20				$ 1,625,637				$ (60)	$ (1,338,091)
Beginning balance (in shares) at Dec. 31, 2023					197,857
Issuance of common stock, net of offering costs (in shares)						150		21,773
Issuance of common stock, net of offering costs		$ 1,037		$ 180,008				$ 2		$ 1,037		$ 180,006
Fees incurred related to common stock financings		(113)		$ (9,741)
Vesting of restricted stock (in shares)					386
Exercise of stock options	4,929								4,929
Exercise of stock options (in shares)					1,120
Stock-based compensation expense	9,092								9,092
Unrealized gain (loss) on marketable securities, net	45												45
Net loss	(107,475)													(107,475)
Ending balance at Mar. 31, 2024	375,142				$ 22				1,820,701				(15)	(1,445,566)
Ending balance (in shares) at Mar. 31, 2024					221,286
Beginning balance at Dec. 31, 2023	287,506				$ 20				1,625,637				(60)	(1,338,091)
Beginning balance (in shares) at Dec. 31, 2023					197,857
Net loss	(217,690)
Ending balance at Sep. 30, 2024	292,478				$ 22				1,848,183				54	(1,555,781)
Ending balance (in shares) at Sep. 30, 2024					223,108
Beginning balance at Mar. 31, 2024	375,142				$ 22				1,820,701				(15)	(1,445,566)
Beginning balance (in shares) at Mar. 31, 2024					221,286
Fees incurred related to common stock financings	(16)								(16)
Vesting of restricted stock (in shares)					52
Exercise of stock options	2,361								2,361
Exercise of stock options (in shares)					548
Issuance of common stock related to employee stock purchase plan	1,077								1,077
Issuance of common stock related to employee stock purchase plan (in shares)					323
Stock-based compensation expense	11,380								11,380
Unrealized gain (loss) on marketable securities, net	(4)												(4)
Net loss	(50,291)													(50,291)
Ending balance at Jun. 30, 2024	339,649				$ 22				1,835,503				(19)	(1,495,857)
Ending balance (in shares) at Jun. 30, 2024					222,209
Fees incurred related to common stock financings	(29)								(29)
Vesting of restricted stock (in shares)					84
Exercise of stock options	1,939								1,939
Exercise of stock options (in shares)					815
Stock-based compensation expense	10,770								10,770
Unrealized gain (loss) on marketable securities, net	73												73
Net loss	(59,924)													(59,924)
Ending balance at Sep. 30, 2024	292,478				$ 22				1,848,183				54	(1,555,781)
Ending balance (in shares) at Sep. 30, 2024					223,108
Beginning balance at Dec. 31, 2024	$ 250,504				$ 22				1,855,318				14	(1,604,850)
Beginning balance (in shares) at Dec. 31, 2024	223,923				223,923
Fees incurred related to common stock financings	$ (171)								(171)
Vesting of restricted stock (in shares)					960
Exercise of stock options	1,127				$ 1				1,126
Exercise of stock options (in shares)					580
Stock-based compensation expense	7,022								7,022
Unrealized gain (loss) on marketable securities, net	(14)												(14)
Net loss	(49,389)													(49,389)
Ending balance at Mar. 31, 2025	209,079				$ 23				1,863,295					(1,654,239)
Ending balance (in shares) at Mar. 31, 2025					225,463
Beginning balance at Dec. 31, 2024	$ 250,504				$ 22				1,855,318				14	(1,604,850)
Beginning balance (in shares) at Dec. 31, 2024	223,923				223,923
Exercise of stock options (in shares)	676
Net loss	$ (185,341)
Ending balance at Sep. 30, 2025	$ 195,308				$ 26				1,985,452				21	(1,790,191)
Ending balance (in shares) at Sep. 30, 2025	262,264				262,264
Beginning balance at Mar. 31, 2025	$ 209,079				$ 23				1,863,295					(1,654,239)
Beginning balance (in shares) at Mar. 31, 2025					225,463
Issuance of common stock, net of offering costs (in shares)						170
Issuance of common stock, net of offering costs		315								315
Exercise of pre-funded warrants (in shares)					4,445
Fees incurred related to common stock financings		(174)
Vesting of restricted stock (in shares)					203
Exercise of stock options	148								148
Exercise of stock options (in shares)					102
Issuance of common stock related to employee stock purchase plan	185								185
Issuance of common stock related to employee stock purchase plan (in shares)					127
Stock-based compensation expense	6,629								6,629
Net loss	(93,800)													(93,800)
Ending balance at Jun. 30, 2025	122,556				$ 23				1,870,572					(1,748,039)
Ending balance (in shares) at Jun. 30, 2025					230,510
Issuance of common stock, net of offering costs (in shares)						7,272	24,254
Issuance of common stock, net of offering costs		28,625	$ 80,625			$ 1	$ 2			$ 28,624	$ 80,623
Fees incurred related to common stock financings		$ (886)	$ (5,625)
Vesting of restricted stock (in shares)					153
Exercise of stock options	158								158
Exercise of stock options (in shares)					75
Stock-based compensation expense	5,475								5,475
Unrealized gain (loss) on marketable securities, net	21												21
Net loss	(42,152)													(42,152)
Ending balance at Sep. 30, 2025	$ 195,308				$ 26				$ 1,985,452				$ 21	$ (1,790,191)
Ending balance (in shares) at Sep. 30, 2025	262,264				262,264